| Methods |
RCT |
| Participants |
Number: 602 patients (? number randomized unknown)
Age: adults |
| Interventions |
meropenem 1grX3
versus
cefepime 2grX3
An addition arm not included in this review assessed piperacillin‐tazobactam + aminoglycoside |
| Outcomes |
Overall mortality.
Other outcomes given only as percentages in a conference presentation without denominators, |
| Notes |
MC Germany |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Randomized multicenter in blocks, block size six |
| Allocation concealment? |
Low risk |
Sealed envelopes, opaque not mentioned. |
| Blinding?
All outcomes |
High risk |
No description |
| Incomplete outcome data addressed?
All‐cause mortality |
Unclear risk |
Number of randomised patients unknown |
| Incomplete outcome data addressed?
Treatment failure |
Unclear risk |
Outcome not reported |
| Free of other bias? |
Low risk |
Unit of randomization = patients |
